NCT04553692 2025-03-28Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed CancersIGM Biosciences, Inc.Phase 1 Terminated272 enrolled
NCT02223052 2020-05-12Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic MalignanciesCelgenePhase 1 Completed89 enrolled